

This listing of claims replaces all prior versions and listings of claims in the Application:

**What is claimed is:**

Claims 1-18 (Cancelled)

19. (New) A method of preventing or controlling testicular bovine viral diarrhea virus infection in a susceptible male animal by administering to the animal an effective amount of a vaccine comprising (a) a modified live type 1 bovine viral diarrhea virus (BVDV); (b) a modified live type 2 BVDV; (c) an inactivated type 1 BVDV; or (d) an inactivated type 2 BVDV; or a combination thereof.

20. (New) The method of claim 19, wherein the animal is selected from the group consisting of a bull, a ram, and a boar.

21. (New) The method of claim 20, wherein the animal is a bull.

22. (New) The method of claim 19, wherein the animal is at increased risk of BVDV testicular infection.

23. (New) The method of claim 19, wherein the vaccine further comprises one or more additional antigens selected from the group consisting of Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), Bovine Respiratory Syncytial Virus (BRSV), *Leptospira canicola*, *Leptospira grippotyphosa*, *Leptospira borgpetersenii hardjo-prajitno*, *Leptospira icterohaemorrhagiae*, *Leptospira interrogans pomona*, *Leptospira borgpetersenii hardjo-bovis*, *Leptospira bratislava*, *Campylobacter fetus*, *Mannheimia (Pasteurella) haemolytica*, *Pasteurella multocida*, *Mycobacterium bovis*, and *Mycobacterium dispar*.

24. (New) The method of claim 23, wherein said additional antigens comprise Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), and Bovine Respiratory Syncytial Virus (BRSV).

25. (New) The method of claim 19, wherein the vaccine comprises both a modified live type 1 BVDV and a modified live type 2 BVDV.

26. (New) The method of claim 25, wherein at least one of the modified live BVDVs is derived from a cytopathogenic virus.

27. (New) The method of claim 25 wherein at least one of the modified live BVDVs is derived from a non-cytopathogenic virus.

28. (New) The method of claim 25, wherein both of the modified live BVDVs are derived from a cytopathogenic virus.

29. (New) The method of claim 25, wherein the vaccine further comprises one or more additional antigens selected from the group consisting of Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), Bovine Respiratory Syncytial Virus (BRSV), *Leptospira canicola*, *Leptospira grippotyphosa*, *Leptospira borgpetersenii hardjo-prajitno*, *Leptospira icterohaemorrhagiae*, *Leptospira interrogans pomona*, *Leptospira borgpetersenii hardjo-ovis*, *Leptospira bratislava*, *Campylobacter fetus*, *Mannheimia (Pasteurella) haemolytica*, *Pasteurella multocida*, *Mycobacterium bovis*, and *Mycobacterium dispar*.

30. (New) The method of claim 25, wherein said additional antigens comprise Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), and Bovine Respiratory Syncytial Virus (BRSV).

31. (New) The method of claim 19, wherein the vaccine comprises both an inactivated type 1 BVDV and an inactivated type 2 BVDV.

32. (New) The method of claim 31, wherein the vaccine further comprises one or more additional antigens selected from the group consisting of Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), Bovine Respiratory Syncytial Virus (BRSV), *Leptospira canicola*, *Leptospira grippotyphosa*, *Leptospira borgpetersenii hardjo-prajitno*, *Leptospira icterohaemorrhagiae*, *Leptospira interrogans pomona*, *Leptospira borgpetersenii hardjo-ovis*, *Leptospira bratislava*, *Campylobacter fetus*, *Mannheimia (Pasteurella) haemolytica*, *Pasteurella multocida*, *Mycobacterium bovis*, and *Mycobacterium dispar*.

33. (New) The method of claim 32, wherein said additional antigens comprise Bovine Herpes Virus (BHV-1), Parainfluenza Virus Type 3 (PIV3), and Bovine Respiratory Syncytial Virus (BRSV).